# SANOVO: HCP commentary report

> 78 verified statements (23 from speakers with a confirmed clinical role) from 54 commentary sources · 7 findings · updated Oct 27, 2026

## Report

- Trial: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
- NCT ID: NCT05009836
- Registry: https://clinicaltrials.gov/study/NCT05009836
- Sponsor: Hutchmed
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: osimertinib
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-27
- Last checked: 2026-10-27
- Release hash: e06e29d94836f077dbec21a44a6fdb596a27fbf4353eb5a447b895e99ca4a983

## Counts

- HCP commentary sources screened: 100
- Sources cited by verified statements: 54
- Verified statements: 78
- From speakers with a confirmed clinical role: 23
- Findings: 7
- People found in screened sources: 20
- People identity-verified: 13
- Voices cited: 20

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

SANOVO asks whether adding savolitinib to first-line osimertinib delays progression in advanced EGFR-mutated, MET-overexpressing NSCLC compared with osimertinib alone. Clinicians in the sources reviewed for this edition differ over readiness for a new standard. They express enthusiasm for upfront dual inhibition while scrutinizing tolerability and survival interpretation. Treatment timing and broader applicability remain open questions in their commentary. SANOVO’s main results are scheduled for ESMO 2026; this reflects commentary before that presentation.

## Open Medical Affairs question

Which baseline MET definition and benefit–toxicity evidence would justify upfront dual blockade rather than another first-line strategy or deferred MET targeting?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Enthusiasm for upfront dual inhibition is not an unconditional endorsement of a new standard
- F2. Baseline MET testing raises both a treatment-selection question and a patient-identification burden
- F3. Tolerability may determine the value of first-line intensification
- F4. When to target MET, and against which alternative, remains an open clinical question
- F5. Strong survival language needs to remain separate from statistical certainty and endpoint identity
- F6. China-specific evidence prompts questions about broader applicability and conditional access
- F7. Congress prioritization signals interest, while wider amplification carries different meanings

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 14 | 12 | 10 | 10 | recorded | 2 |
| F2 | 8 | 9 | 9 | 8 | none recorded | 2 |
| F3 | 8 | 9 | 9 | 8 | recorded | 2 |
| F4 | 9 | 8 | 8 | 8 | none recorded | 2 |
| F5 | 22 | 21 | 20 | 17 | recorded | 2 |
| F6 | 7 | 7 | 7 | 7 | none recorded | 2 |
| F7 | 26 | 26 | 24 | 20 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 9 | 2 | 0 | 3 | 0 | 16 | 0 | 9 posts and articles, 1 podcast or video | yes |
| F2 | 3 | 4 | 0 | 0 | 1 | 10 | 0 | 8 posts and articles, 1 podcast or video | yes |
| F3 | 3 | 2 | 0 | 1 | 2 | 9 | 0 | 9 posts and articles | yes |
| F4 | 4 | 3 | 0 | 2 | 0 | 10 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F5 | 6 | 2 | 0 | 0 | 14 | 24 | 1 | 18 posts and articles, 2 podcasts and video | yes |
| F6 | 2 | 0 | 0 | 1 | 4 | 7 | 0 | 7 posts and articles | yes |
| F7 | 11 | 0 | 0 | 0 | 15 | 33 | 6 | 24 posts and articles | yes |

### Trial dimensions

- Primary endpoint: PFS: F1 (2 shared claims), F2 (2 shared claims), F3 (2 shared claims), F5 (12 shared claims), F6 (1 shared claims), F7 (9 shared claims)
- Secondary endpoints: F1 (4 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (2 shared claims), F5 (17 shared claims), F6 (1 shared claims), F7 (2 shared claims)
- Population and setting: F1 (8 shared claims), F2 (7 shared claims), F3 (1 shared claims), F4 (5 shared claims), F5 (6 shared claims), F6 (4 shared claims), F7 (7 shared claims)
- The comparison: F1 (7 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (6 shared claims), F5 (7 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Safety and tolerability: F1 (4 shared claims), F3 (8 shared claims), F4 (1 shared claims), F5 (3 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (4 shared claims), F6 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 78 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 54 | Counts free |
| Speaker attribution for cited voices | 20 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: PFS | discussed | 22 | 23 |
| Secondary endpoints | discussed | 20 | 19 |
| Population and setting | discussed | 27 | 24 |
| The comparison | discussed | 15 | 15 |
| Safety and tolerability | discussed | 8 | 9 |
| Design and conduct | discussed | 5 | 5 |
| Timing of MET targeting and alternative first-line regimens | discussed | 12 | 11 |
| MET assays, thresholds and practical patient identification | discussed | 7 | 8 |
| Broader applicability, patient communication and conditional regulatory implications | discussed | 6 | 6 |
| Congress prioritization and wider communication framing | discussed | 17 | 16 |
| Evidence maturity, statistical interpretation and readiness for practice | discussed | 16 | 13 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 88 | 51 |
| Bluesky threads | 9 | 1 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 0 |

- Screened window: 2021-09-08 to 2026-10-26
- Cited window: 2021-09-08 to 2026-10-26
- Retrieved: 2026-10-27

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
- Registry: NCT05009836 (https://clinicaltrials.gov/study/NCT05009836)
- Study IDs: 2020-504-00CH4
- Sponsor: Hutchmed
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 412 (estimated)
- Start: 2021-09-06 (actual)
- Primary completion: 2028-05-30 (estimated)
- Primary endpoint: PFS (17 months after the last patient enrolled)
- Intervention: Savolitinib (drug)
- Intervention: Placebo (drug)
- Intervention: Osimertinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.
- Some potentially relevant passages were not fully assessed. Unnamed references and differently worded trial references may be missing.
- No trial protocol, exact-trial results publication or matching product-label documents were available, limiting independent assessment of methods, results and regulatory status.
- Several numerical findings are second-hand accounts of conference talks. Their reporting does not establish details that the account itself omits.
- PFS HRs differ between commentators, and the reviewed material does not explain those differences.
- The reviewed statements do not provide a complete safety analysis or establish statistical significance for OS.
- The clinical roles of Alex Ehsan, Adam Januszewski and Minhua Chu are not established in the sources reviewed. The interview identifies Qing Zhou, but independent identity confirmation is unavailable. Several other comments are from unnamed speakers whose identities and clinical roles are unknown.
- The report spans different evidence stages. Earlier requests for full data should not be read as later reactions, and post dates do not prove session dates or changes of mind.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-27: current edition

Last checked for new commentary 2026-10-27. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (78 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (13 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/sanovo-nct05009836
- Agents: POST https://www.erudio.com/api/orders with {"report": "sanovo-nct05009836", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=sanovo-05009836

## Cite

Erudio Health. SANOVO (NCT05009836): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 27, 2026. https://www.erudio.com/reports/sanovo-nct05009836

## Machine access

- JSON: https://www.erudio.com/reports/sanovo-nct05009836.json
- Markdown: https://www.erudio.com/reports/sanovo-nct05009836.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "sanovo-05009836"}`